Replimune Group, Inc. (REPL) Form 8-K — Oct 28, 2026
Replimune reported fiscal Q2 2027 results on October 28, 2026, its first quarter with newly approved TUDRIQEV commercially available in the U.S. for advanced melanoma in combination with nivolumab, with first patient delivery on October 6 and more than 15 institutions already prescribing. The launch is off to a fast start: over 70% of its initial 200 priority accounts have been engaged, leading melanoma centers have placed TUDRIQEV on formulary, and NCCN category 2A inclusion has enabled broad payer coverage.
Key figures
- Revenue
- 0
- Total Assets
- 373940000
- Cash Position
- 307800000
- Tranche4 debt draw
- 15000000
- Net loss prior year q2
- 83100000
- R and d expense q2 fy26
- 57900000
- R and d expense q2 fy27
- 34400000
- Institutions prescribing
- more than 15
- Sg and a expense q2 fy26
- 26400000
- Sg and a expense q2 fy27
- 21900000
- Priority accounts engaged pct
- >70% of initial 200
- August 2026 offering net proceeds
- 141000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.